BioPharma Resources

Drug Trial Radar · NCT06931080

Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients

A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Trial to Evaluate the Efficacy and Safety of EB-1020 Once Daily QD XR Capsules Administered Orally at Low or High Dose in Adults With Attention-deficit/Hyperactivity Disorder

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 630 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

630

Planned (sponsor's estimate)

Start

Apr 30, 2025

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Sponsor type
Industry
First posted
Apr 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and examine the safety of two doses of EB-1020 QD XR capsule administered once daily orally in adult ADHD patients.

Conditions

  • Attention Deficit Hyperactivity Disorder (ADHD)

Interventions

  • EB-1020 (Centanafadine) 164.4 mgDrug

    164.4 mg, capsule, oral, once daily, for 6 weeks

  • EB-1020 (Centanafadine) 328.8 mgDrug

    328.8 mg, capsule, oral, once daily, for 6 weeks

  • PlaceboDrug

    Placebo, capsule, oral, once daily, for 6 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Adult ADHD Investigator Symptom Rating Scale (AISRS) score at Week6Time frame: Baseline, Weeks 6

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Maynds Tower Mental Clinic

    Tokyo, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.